<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00832442</url>
  </required_header>
  <id_info>
    <org_study_id>CTEU08/d5/BBHF</org_study_id>
    <nct_id>NCT00832442</nct_id>
  </id_info>
  <brief_title>Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure</brief_title>
  <acronym>BB-META-HF</acronym>
  <official_title>Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several large trials have shown that beta-blocker treatment reduces the risk of death and
      hospital admission in patients with symptomatic heart failure. Unfortunately, survey data
      suggests relatively poor utilisation of beta-blockers, despite ample evidence for good
      tolerability. Additionally there are several important unanswered questions, such as clinical
      efficacy for specific sub-populations (women, the elderly and patients with diabetes or other
      co-morbidities) and the effect of beta-blockers in combination with other medications.
      Previous meta-analyses, based on published tabular data, have been conducted although this
      approach has important biases and limitations.

      We plan to perform a carefully conducted systematic review of individual patient data from
      the major randomised trials of beta-blockers in heart failure. The goals of this
      collaborative project are to clarify the overall efficacy of beta-blockers and identify
      sub-groups that show particular benefit, thereby increasing the use of beta-blockers,
      reducing adverse clinical outcomes and the high costs associated with this condition.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Beta-blocker therapy improves overall mortality and morbidity in symptomatic heart failure in an individual patient meta-analysis</measure>
    <time_frame>variable (time to event)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta-blocker therapy improves mortality and morbidity in both elderly patients and women</measure>
    <time_frame>variable (time to event)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-blocker therapy improves mortality and morbidity in patients with co-morbidities (diabetes, renal dysfunction, COPD, peripheral arterial disease or atrial fibrillation)</measure>
    <time_frame>variable (time to event)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The benefit of beta-blockers is not modified by concomitant cardiovascular therapy</measure>
    <time_frame>variable (time to event)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The benefit of beta-blockers is independent of left ventricular ejection fraction at baseline</measure>
    <time_frame>variable (time to event)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical benefit is dependent on the resting heart rate achieved whatever the dose achieved or agent used</measure>
    <time_frame>variable (time to event)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse side effects of beta blocker therapy do not significantly impact on clinical benefit (as a whole and in relevant sub-groups)</measure>
    <time_frame>variable (time to event)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">18240</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Beta blocker</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta blocker</intervention_name>
    <description>as determined by individual study</description>
    <arm_group_label>Beta blocker</arm_group_label>
    <other_name>Metoprolol</other_name>
    <other_name>Bucindolol</other_name>
    <other_name>Carvedilol</other_name>
    <other_name>Bisoprolol</other_name>
    <other_name>Nebivolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>in addition to usual care</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Meta-Analysis of randomised controlled trials investigating mortality &amp; morbidity of
        placebo versus beta-blockers in heart failure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Randomised control trials of beta-blocker versus control in patients with documented
             heart failure

          -  Unconfounded trials only (in which one treatment group differed from another only by
             the beta-blocker therapy of interest)

          -  Randomization process precluded prior knowledge of the next treatment (for example
             trials in which treatment allocation was alternate or based on odd or even dates would
             not be included)

        Exclusion Criteria:

          -  Trial sample size of less than 300 patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Flather</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Brompton Hospital, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Manzano</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Alcala, Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dipak Kotecha</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Brompton Hospital, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henry Krum</last_name>
    <role>Study Chair</role>
    <affiliation>Monash University, Melbourne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trials &amp; Evaluation Unit, Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Statistics in Medicine, University of Oxford</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.rbht.nhs.uk/cteu/</url>
    <description>Clinical Trials &amp; Evaluation Unit</description>
  </link>
  <link>
    <url>http://www.ccretherapeutics.org.au/</url>
    <description>Monash Centre of Cardiovascular Research &amp; Education (CCRE) in Therapeutics</description>
  </link>
  <reference>
    <citation>Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993 Dec 11;342(8885):1441-6.</citation>
    <PMID>7902479</PMID>
  </reference>
  <reference>
    <citation>A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994 Oct;90(4):1765-73.</citation>
    <PMID>7923660</PMID>
  </reference>
  <reference>
    <citation>Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet. 1997 Feb 8;349(9049):375-80.</citation>
    <PMID>9033462</PMID>
  </reference>
  <reference>
    <citation>Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349-55.</citation>
    <PMID>8614419</PMID>
  </reference>
  <reference>
    <citation>The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9-13.</citation>
    <PMID>10023943</PMID>
  </reference>
  <reference>
    <citation>Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651-8.</citation>
    <PMID>11386263</PMID>
  </reference>
  <reference>
    <citation>Beta-Blocker Evaluation of Survival Trial Investigators, Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001 May 31;344(22):1659-67.</citation>
    <PMID>11386264</PMID>
  </reference>
  <reference>
    <citation>Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, BÃ¶hm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 Feb;26(3):215-25. Epub 2005 Jan 9.</citation>
    <PMID>15642700</PMID>
  </reference>
  <reference>
    <citation>Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001 May 5;357(9266):1385-90.</citation>
    <PMID>11356434</PMID>
  </reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2009</study_first_submitted>
  <study_first_submitted_qc>January 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2009</study_first_posted>
  <last_update_submitted>May 8, 2012</last_update_submitted>
  <last_update_submitted_qc>May 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Beta blocker</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Meta analysis</keyword>
  <keyword>Individual patient data</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

